Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Price Breaks Above Two Hundred Day Moving Average - What's Next?

Key Points

• Cumberland Pharmaceuticals shares broke above their 200-day moving average, reaching $8.14 before last trading at $7.51, compared with a 200-day average of $5.81.
• Analysts remain bearish: Weiss Ratings reiterated a “sell (D-)” rating, and MarketBeat reports an average rating of “Sell.”
• The company’s latest quarterly results were weak, with an adjusted loss of $0.20 per share versus a forecasted loss of $0.13 and revenue of just $0.17 million against estimates of $8.50 million.

Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report) crossed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $5.81 and traded as high as $8.14. Cumberland Pharmaceuticals shares last traded at $7.51, with a volume of 73,339 shares traded.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of Cumberland Pharmaceuticals in a research note on Monday, September 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Cumberland Pharmaceuticals currently has an average rating of "Sell".

Cumberland Pharmaceuticals Stock Down 4.1%

The firm has a market capitalization of $112.50 million, a price-to-earnings ratio of -10.58 and a beta of 0.06. The company has a fifty day moving average price of $7.39 and a two-hundred day moving average price of $5.81.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last announced its earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.07). The business had revenue of $0.17 million during the quarter, compared to analyst estimates of $8.50 million. Cumberland Pharmaceuticals had a negative net margin of 34.40% and a negative return on equity of 28.81%.

Cumberland Pharmaceuticals Dividend Announcement

The firm also recently disclosed a dividend, which was paid on Friday, July 31st. Shareholders of record on Thursday, July 23rd were paid a $1.50 dividend.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Arrowstreet Capital Limited Partnership acquired a new position in Cumberland Pharmaceuticals in the 1st quarter valued at $66,000. Bank of New York Mellon Corp acquired a new stake in shares of Cumberland Pharmaceuticals in the 2nd quarter worth $379,000. BlackRock Inc. acquired a new stake in shares of Cumberland Pharmaceuticals in the 2nd quarter worth $412,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Cumberland Pharmaceuticals by 1.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 276,359 shares of the specialty pharmaceutical company's stock worth $898,000 after acquiring an additional 4,081 shares during the period. Institutional investors and hedge funds own 15.51% of the company's stock.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, acquisition and commercialization of prescription products for hospital care, gastroenterology and other targeted therapeutic areas. The company's business model emphasizes branded medicines that address specific clinical needs and are marketed primarily in the United States.

Its product portfolio has included Acetadote (acetylcysteine injection), used in the treatment of acetaminophen poisoning; Caldolor (ibuprofen injection), an intravenous nonsteroidal anti-inflammatory drug for pain and fever; and Kristalose (lactulose), a prescription treatment for constipation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.